A Case Series on the Impact of Abiraterone Acetate with Prednisone in Metastatic Prostate Adenocarcinoma: The Real World Experience

Abstract

Objective: To evaluate the clinical benefit of Abiraterone acetate plus prednisone (AA + P) with androgen deprivation therapy in patients with metastatic prostate cancer as a local experience in the Philippines.

Materials and Methods: The authors evaluated retrospectively a case series of seven patients receiving androgen deprivation therapy with high-risk metastatic castration-sensitive prostate cancer (mCSPC) and metastatic castration-resistant prostate cancer (mCRPC) treated with AA + P in a tertiary hospital from April 2019 to October 2020. Disease characteristics, biochemical trend, quality of life evaluation using the European Organization for Research and Treatment of Cancer Questionnaire (EORTC QLQ-C30 v.3), and adverse events reporting using Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 were all retrieved from the medical records as outcome measures.

Results: Analysis of 18 months period using chart review was done. Five patients showed clinical improvement on positive PSA response. Patients also presented with Grade 1-2 adverse events score based on CTCAE including hypertension, hepatotoxicity, gastrointestinal symptoms, and electrolyte imbalances. Using the EORTC QLQ-C30 v.3 showed that AA + P provided significant improvement on the overall quality of life, functioning in terms of role, emotional, cognitive and social aspects with reasonable safety profile and minimal adverse events limited to worsening of gastrointestinal symptoms from baseline.

Conclusion: The addition of AA + P to androgen deprivation therapy is a suitable option for both high-risk mCSPC and mCRPC exhibiting a significant biochemical, functional and quality of life improvement with reasonable safety profile and limited adverse events in the ‘real-world’ setting, which is comparable with the findings in other similar studies.